Skip to content
Stock screener

CELZ Creative Medical Technology Holdings, Inc. stock chart & analysis

Conviction 45HealthcareScan · Wed, Nov 18, 2026
Tweezer bottom

Creative Medical Technology Holdings, Inc. (CELZ) closed at $0.4694 (-1.51%) on Nov 18, 2026. Its latest daily candle is a tweezer bottom. Price is below its 50-day and below its 200-day moving average. RSI(14) 25, RS Rating 4, -90.0% from its 52-week high, -76.0% year to date. Sector: Healthcare · Biological Products, (No Diagnostic Substances).

CELZ$0.4694-1.51%
ResistanceSupportVol 14
Loading chart…

Why CELZ moved

From the StockSetups movers recaps that covered CELZ, newest first. A recap states what was known that day.

Creative Medical Technology Holdings, Inc.Biological Products, (No Diagnostic Substances)www.creativemedicaltechnology.com ↗
Price0.4694
Change-1.51%
Gap-3.21%
Rel volume0.36×
Avg volume88.18K
Avg $ vol54.94K
SMA 200.6300
SMA 500.7855
SMA 2001.48
Price vs 50-40.24%
Price vs 200-68.32%
MA stackbearish
50/200 cross—
Supertrenddown · 0.6281
RSI (14)25
MACD hist-0.01
MACD crossbear · 3d
Stoch %K / %D3 / 3
ADX (14)43
+DI / −DI7 / 33
RSI divergence—
MACD divergenceBullish
ATR %12.33%
ADR %8.79%
52w high4.72
52w low0.4607
From 52w high-90.05%
Above 52w low+1.89%
New 52w highNo
SqueezeOff
Bollinger width51.27%
%B0.00
Donchian pos2.73%
Donchian high0.7798
Donchian low0.4607
AVWAP (52w high)1.62
vs AVWAP high-71.06%
AVWAP (52w low)0.4815
vs AVWAP low-2.52%
OBV trendDown
Chaikin MF (20)-0.34
Today vs 20d0.36×
Avg vol (14d)96.04K
Avg vol (20d)88.18K
Avg $ vol (20d)54.94K
Market cap—
RS Rating4 / 99
RS 3m (vs SPY)-59.10%
RS 6m (vs SPY)-77.85%
RS line new highNo
Trend template0/8
Technical rank6.3
1 week-25.44%
1 month-37.80%
3 months-63.33%
6 months-79.32%
1 year-84.61%
YTD-76.05%
P/E-0.60
P/B0.52
P/S603.50
P/FCF—
EPS-2.52
Div yield—
ROE-86.20%
ROA-82.36%
Debt/Eq0.74
Current23.66
EV/EBITDA—
Gross margin63.43%
Net margin—
Rev growth-45.45%
EPS growth-9.13%
Price target—
Target upside—
Analyst rating—
Institutional—
Ent. value1.92M
Revenue0
Net income-2.67M
Gross profit0
Free cash flow—
IndustryBiological Products, (No Diagnostic Substances)
ExchangeNasdaq
Shares out3.7M
Employees4
ListedThu, Apr 30, 2009
Free float—
Float %—
Short interest—
Days to cover—
Short volume—
Squeeze score—
Next earnings—
EPS forecast—
Last EPS vs est—
Last surprise—
Setup gradeD
Conviction45 / 100
Pattern quality—
Tech rank6.3 / 100
Group rank14 / 100
Status lane—
Setup direction—
Pattern family
Resistance—
Support—
Days since event—
Candle confirmTweezer bottom

Financials as of Wed, Sep 30, 2026 · quarterly.

CELZ technical analysis

Trend

CELZ is in a downtrend: price is below the 50-day, which is below the 200-day moving average. It closed 40.2% below the 50-day ($0.7855) and 68.3% below the 200-day ($1.48). ADX(14) at 43 points to a strong, established trend. It meets 0 of 8 trend-template criteria.

Momentum

RSI(14) is 25, in oversold territory. MACD crossed below its signal line 3 sessions ago. A bullish MACD divergence is in place. Its RS Rating of 4 puts its weighted 12-month performance ahead of about 4% of the US market.

Volume and volatility

Volume on the latest session ran 0.4× its 20-day average. It trades about $54,940 a day on average. ATR(14) is $0.0579, 12.3% of price — its typical daily range. On-balance volume is trending down. Chaikin Money Flow (-0.34) shows distribution.

Key levels

The 52-week range is $0.4607 to $4.72; price is 90.0% below the high and 1.9% above the low. The VWAP anchored at the 52-week high is $1.62, above price.

Performance

CELZ returned -25.4% (1 week), -37.8% (1 month), -63.3% (3 months), -79.3% (6 months), -84.6% (1 year), -76.0% (year to date).

About Creative Medical Technology Holdings, Inc.

Creative Medical Technology Holdings Inc is a commercial-stage biotechnology company focused on the advancement of regenerative therapies in the fields of immunotherapy, endocrinology, urology, neurology, and orthopedics. Its pipeline consists of AlloStem (CELZ-201-DDT); ImmCelz (CELZ-100), a personalized supercharged immune therapy platform; CELZ-201 CREATE-1, an intervention for the treatment of recent onset Type 1 Diabetes; AlloStemSpine for treatment of lower back pain; the Alova program to treat infertility as a result of premature ovarian failure; and other regenerative treatment programs and technologies like OvaStem, CaverStem, FemCelz, StemSpine, and others for the treatment of various indications related to sexual health, spine disc disease, kidney failure, liver failure, etc.

Biological Products, (No Diagnostic Substances) · Listed 2009 · 4 employees

SEC filings

EDGAR filings in CELZ · 10 recent

EDGAR →

Get daily signals & real-time alerts.

StockSetups scans ~12,300 US stocks & ETFs after every close and sorts every long setup into four ranked lanes — each with a trade plan — plus an always-on engine firing 35+ real-time intraday alerts. Free for 7 days, no credit card.

Start free — 7-day trial, no card →

Educational data, not financial advice. Patterns, levels and the trade plan are algorithmic, not a recommendation to trade.